Tag: Cholestatic liver diseases
Mirum gets FDA breakthrough therapy status for maralixibat for Alagille syndrome
Mirum Pharmaceuticals has secured the breakthrough therapy designation for maralixibat from the US Food and Drug Administration (FDA) for the treatment of pruritus associated with ... Read More
Mirum Pharmaceuticals raises $120m to advance Maralixibat into phase 3
Mirum Pharmaceuticals, a clinical stage pharma company in San Diego, has raised $120 million in a Series A funding round to support the development of ... Read More